Key result
Percutaneous coronary intervention significantly decreased serum Angiopoietin-2 concentrations in patients with coronary heart disease from 4625.06 pg/ml to 3042.63 pg/ml.
Why the study?
Does percutaneous coronary intervention reduce serum Angiopoietin-2 concentrations in patients with coronary heart disease?
Population
64 patients with coronary heart disease undergoing PCI, and 32 healthy subjects as controls.
Comparison
Percutaneous coronary intervention (PCI) vs Pre-PCI baseline and healthy subjects
Design
Cohort
Authors
Loading...
PCI-associated Ang-2 reduction should not yet change practice; leaves open its prognostic or therapeutic role in coronary disease.
Observational (n=96)
No
Does percutaneous coronary intervention reduce serum Angiopoietin-2 concentrations in patients with coronary heart disease?
Absolute Event Rate: 3042.63% vs 4625.06%
p-value: p=<0.01
PCI significantly decreases elevated serum Ang-2 concentrations in patients with CHD, suggesting Ang-2 may serve as a biomarker for myocardial ischemia and vessel remodeling.
Zeng et al. (2016) conducted an observational in Coronary Heart Disease (n=96). Percutaneous coronary intervention (PCI) vs. Pre-PCI baseline was evaluated on Serum Angiopoietin-2 (Ang-2) concentrations (p=<0.01). Percutaneous coronary intervention significantly decreased serum Angiopoietin-2 concentrations in patients with coronary heart disease from 4625.06 pg/ml to 3042.63 pg/ml.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: